USFDAJun 29, 2026, 07:06 AM
Satellos Receives FDA Fast Track for SAT-3247 in Duchenne
AI Summary
Satellos Bioscience announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne Muscular Dystrophy (DMD). This designation, along with prior Orphan Drug and Rare Pediatric Disease designations, aims to expedite the development and review of the drug. The company is currently advancing SAT-3247 through its Phase 2 BASECAMP and TRAILHEAD studies, with additional data anticipated in the second half of 2026.
Key Highlights
- Satellos' SAT-3247 received FDA Fast Track designation.
- Designation is for the treatment of Duchenne Muscular Dystrophy (DMD).
- SAT-3247 previously received Orphan Drug and Rare Pediatric Disease designations.
- Fast Track expedites development and review for serious conditions.
- Company may receive more frequent FDA interactions and rolling review.
- Phase 2 BASECAMP and TRAILHEAD studies for DMD are ongoing.
- Additional data from Phase 2 studies is expected in 2H 2026.
Price Impact
More from MSLE